Therapeutic Modulation of the Marrow Microenvironment in MDS: A Phase I Trial of Abaloparatide and Bevacizumab

MLA

Jozal W. Moore, et al. “Therapeutic Modulation of the Marrow Microenvironment in MDS: A Phase I Trial of Abaloparatide and Bevacizumab.” Blood, vol. 140, Nov. 2022, pp. 4050–52. EBSCOhost, https://doi.org/10.1182/blood-2022-159515.

APA

Jozal W. Moore, Jason H. Mendler, Kah Poh (melissa) Loh, Mitra Azadniv, Kristen M. O’Dwyer, Eric J. Huselton, Frank Akwaa, Benjamin J. Frisch, Myla Strawderman, Mark W. LaMere, Daniel K. Byun, Alyssa C. Jasper, Michael W. Becker, Jane L. Liesveld, & Laura M. Calvi. (2022). Therapeutic Modulation of the Marrow Microenvironment in MDS: A Phase I Trial of Abaloparatide and Bevacizumab. Blood, 140, 4050–4052. https://doi.org/10.1182/blood-2022-159515

Chicago

Jozal W. Moore, Jason H. Mendler, Kah Poh (melissa) Loh, Mitra Azadniv, Kristen M. O’Dwyer, Eric J. Huselton, Frank Akwaa, et al. 2022. “Therapeutic Modulation of the Marrow Microenvironment in MDS: A Phase I Trial of Abaloparatide and Bevacizumab.” Blood 140 (November): 4050–52. doi:10.1182/blood-2022-159515.